There are number of challenges in the elimination of the three blood-borne viruses — HIV, hepatitis B (HBV), and hepatitis C (HCV). Treatment advances have been made with the introduction of highly effective antiviral agents into clinical practice, and prevention strategies. However, for worldwide elimination of these viruses, effective vaccines are required. Dr Marina Klein (McGill University Health Centre, Montreal, Canada) joins touchINFECTIOUS DISEASES to discuss the global health burden of HIV, HBV and HCV, the challenges associated with the elimination of these viruses, and a look at future therapeutic developments.
The presentation entitled ‘Triple elimination: HIV, HCV, HBV’ was presented at the International AIDS Society (IAS) 29 July – 2 August, 2022.
- Could you tell us a little about the global health burden of human immunodeficiency virus (HIV), hepatitis B (HBV) and hepatitis C (HCV)? (00:16)
- What are the challenges of elimination of HIV, HBV and HCV and how may they be overcome? (00:56)
- What therapeutic developments do you anticipate in the coming years? (02:34)
Disclosures: Marina Klein is a consultant for Gilead Science; receives grant/research support from Abbvie, Gilead Sciences, and ViiV Healthcare; and is on the advisory board for Abbvie, and ViiV Healthcare.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Shanice Allen.
Share this Video
Related Videos In HIV
Updated HIV primary care guidelines: Mamta Jain, ACTHIV 2023
Updated HIV primary care guidelines provide evidence-based and standardized approaches to manage individuals living with HIV, addressing their unique needs and challenges. By following these guidelines, healthcare providers can enhance patient outcomes and stay abreast of the latest research and treatment advancements in HIV care. In this interview, we speak with Dr Mamta Jain (UT […]
Managing liver complications and drug-drug interactions in HBV-HIV co-infection: ACTHIV 2023 with Jessie Torgersen
Liver complications and drug-drug interactions in HBV viremia in HIV patients are common, so it is important to consider complications and follow appropriate guidelines for patients when prescribing treatment. In this interview, we speak with Dr Jessie Torgersen (University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA) to explore considerations for healthcare professionals, including liver complications […]
HIV-HBV co-infection screening and monitoring guidelines: ACTHIV 2023, Jessie Torgersen
Screening and managing HIV-hepatitis B virus (HBV) co-infection is important due to increased risks in patients, therefore it is important to ensure standard practices involve comprehensive assessment, including serological testing and liver function evaluation, and healthcare professionals follow guidelines for regular monitoring to assess disease progression and treatment response. In this interview, we speak with […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!